Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report
Mepolizumab (MEP) is the first anti Interleukin (IL)-5 add-on therapy approved for the treatment of severe refractory eosinophilic asthma.
Source: Allergy, Asthma and Clinical Immunology - Category: Allergy & Immunology Authors: C. Caruso, S. Colantuono, D. Pugliese, C. Di Mario, B. Tolusso, E. Gremese, G. Papparella, F. Castr ì, A. Gasbarrini, A. Romano and A. Armuzzi Tags: Case report Source Type: research
More News: Allergy | Allergy & Immunology | Aspirin | Asthma | Gastroenteritis | Gastroenterology | Respiratory Medicine